Regeneron Files 8-K on Results, Reg FD Disclosure

Ticker: REGN · Form: 8-K · Filed: Jan 8, 2024 · CIK: 872589

Regeneron Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyRegeneron Pharmaceuticals, Inc. (REGN)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages5
Reading Time5 min
Key Dollar Amounts$0.001, $123 million, $1.34 billion, $30 million, $0.21
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, financial-condition, corporate-disclosure

TL;DR

**Regeneron just dropped an 8-K, signaling new financial info is out; watch for details!**

AI Summary

Regeneron Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to disclose information under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This filing indicates that the company is providing an update on its financial performance or other material non-public information, likely in preparation for an upcoming earnings report or investor event. For investors, this matters because it signals that new financial data or significant operational updates are being made public, which could influence the stock price (REGN) as the market digests this information.

Why It Matters

This filing signals that Regeneron is releasing new financial or operational information, which could impact investor sentiment and the stock's valuation. Investors should look for the specific details of the disclosure to understand the implications.

Risk Assessment

Risk Level: medium — The risk is medium because while the filing itself is procedural, the undisclosed content under Items 2.02 and 7.01 could contain positive or negative news impacting the stock.

Analyst Insight

A smart investor would immediately seek out the full content of the 8-K filing, particularly any exhibits or attachments, to understand the specific financial results or disclosures made under Items 2.02 and 7.01, as these will contain the actual news impacting the company.

Key Players & Entities

  • REGENERON PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
  • January 8, 2024 (date) — date of earliest event reported and filing date
  • 000-19034 (string) — Commission File Number for Regeneron
  • 13-3444607 (string) — I.R.S. Employer Identification No. for Regeneron
  • REGN (string) — Trading Symbol for Regeneron's Common Stock

FAQ

What specific items did Regeneron Pharmaceuticals, Inc. report under in this 8-K filing?

Regeneron Pharmaceuticals, Inc. reported under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits) in this 8-K filing dated January 8, 2024.

What is the filing date and the date of the earliest event reported for this 8-K?

Both the filing date and the date of the earliest event reported for this 8-K are January 8, 2024.

What is the trading symbol and the exchange where Regeneron's Common Stock is registered?

Regeneron's Common Stock trades under the symbol REGN and is registered on the NASDAQ Global Select Market.

What is Regeneron Pharmaceuticals, Inc.'s business address?

Regeneron Pharmaceuticals, Inc.'s business address is 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707.

What is the significance of Item 7.01 (Regulation FD Disclosure) in this 8-K?

Item 7.01 (Regulation FD Disclosure) indicates that Regeneron is making public material non-public information, ensuring fair and broad disclosure to all investors simultaneously, rather than selectively.

Filing Stats: 1,366 words · 5 min read · ~5 pages · Grade level 11.2 · Accepted 2024-01-08 06:30:44

Key Financial Figures

  • $0.001 — h registered Common Stock – par value $0.001 per share REGN NASDAQ Global Select M
  • $123 million — ercept) Injection 8 mg of approximately $123 million and the Company's preliminary (unaudite
  • $1.34 billion — aflibercept) Injection of approximately $1.34 billion. Additionally, the Company currently e
  • $30 million — h and development (" IPR&D ") charge of $30 million on a pre-tax basis. This charge relates
  • $0.21 — he fourth quarter 2023 by approximately $0.21. Acquired IPR&D charges may include IP

Filing Documents

02

Item 2.02. Results of Operations and Financial Condition. On January 8, 2024, at the 42nd Annual J.P. Morgan Healthcare Conference, Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc. (" Regeneron " or the " Company "), and George D. Yancopoulos, M.D., Ph.D., Board Co-Chair, President and Chief Scientific Officer of Regeneron, are providing a corporate update. The presentation includes information regarding the Company's preliminary (unaudited) fourth quarter 2023 U.S. net product sales of EYLEA HD (aflibercept) Injection 8 mg of approximately $123 million and the Company's preliminary (unaudited) fourth quarter 2023 U.S. net product sales of EYLEA (aflibercept) Injection of approximately $1.34 billion. Additionally, the Company currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (" GAAP ") and its non-GAAP financial results for the fourth quarter 2023 will include an acquired in-process research and development (" IPR&D ") charge of $30 million on a pre-tax basis. This charge relates to a payment to extend the Company's collaboration with Intellia Therapeutics, Inc. This acquired IPR&D charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted share for the fourth quarter 2023 by approximately $0.21. Acquired IPR&D charges may include IPR&D acquired in connection with asset acquisitions as well as up-front, opt-in, and certain development milestone payments related to collaboration and licensing agreements. Regeneron does not forecast such acquired IPR&D charges due to the uncertainty of the future occurrence, magnitude, and timing of these transactions in any given period. Regeneron's results for the fourth quarter 2023 have not been finalized and are subject to Regeneron's financial statement closing procedures. There can be no assurance that actual results will not differ from the preli

01

Item 7.01. Regulation FD Disclosure. The information set forth under Item 2.02 of this Current Report on Form 8-K is incorporated by reference herein. A copy of the presentation referenced in Item 2.02 is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 7.01. The information included in Item 2.02 and the information included or incorporated in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 99.1 Presentation by Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc., and George D. Yancopoulos, M.D., Ph.D., Board Co-Chair, President and Chief Scientific Officer of Regeneron Pharmaceuticals, Inc., at the 42nd Annual J.P. Morgan Healthcare Conference. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. Note Regarding Forward-Looking Statements This Current Report on Form 8-K (this "Report") includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, Regeneron's expectations with respect to commercialization of its marketed products (including EYLEA HD (aflibercept) Injection 8 mg and EYLEA (aflibercept) Injection), competitive and other relevant developments affecting the market share of Regeneron's marketed products, and other relevant factors (whether within or without Regeneron's control) impacting the degree to which commercialization of Regeneron's marketed products is successful, as well as the impact of any of the foregoing on Regeneron's results of operations; Regeneron's expected acquired in-process research and development charge for the quarterly period ended December 31, 2023 and its expected impact on GAAP and non-GAAP net income per diluted share for this period as discussed in

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REGENERON PHARMACEUTICALS, INC. /s/ Joseph J. LaRosa Joseph J. LaRosa Executive Vice President, General Counsel and Secretary Date: January 8, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.